MAPT and Parkinson disease: Due to this gap, it may be worthwhile in the future to analyze APOE4’s impact on tau pathology in PD-related cognitive impairment and DLB using neuroimaging, given the prevalence of tau aggregation in these disorders, and APOE4’s known association with tau in AD.